Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1084/jem.20151778 http://scihub22266oqcxt.onion/10.1084/jem.20151778 C5748843!5748843!29158376     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Exp+Med 2018 ; 215 (1): 197-216 Nephropedia Template TP {{tp|p=29158376|t=2018. Leukemia-specific delivery of mutant NOTCH1 targeted therapy |pdf=|usr=}}{{29158376}} gab.com Text Leukemia-specific delivery of mutant NOTCH1 targeted therapy JO: J Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=29158376 #FOAvip NOTCH1 is an attractive cancer target, particularly in T cell acute lymphoblastic leukemia (T-ALL), with activating mutations in this gene identified in more than 50% of cases. In this study, Roti et al. describe the synthesis, characterization, and validation of JQ-FT, a first-in-class NOTCH1 inhibitor that has dual selectivity for leukemia over normal cells and NOTCH1 mutants over wild-type receptors. Twit Text FOAVip Leukemia-specific delivery of mutant NOTCH1 targeted therapy ????J Exp Med http://www.kidney.de/pget.php?&tw=1&pmid=29158376 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29158376 #FOAvip English Wikipedia <ref>{{Cite pmid|29158376}}</ref> Leukemia-specific delivery of mutant NOTCH1 targeted therapy #MMPMID29158376 Roti G; Qi J; Kitara S; Sanchez-Martin M; Saur Conway A; Varca AC; Su A; Wu L; Kung AL; Ferrando AA; Bradner JE; Stegmaier K J Exp Med 2018[Jan]; 215 (1): 197-216 PMID29158376show ga NOTCH1 is an attractive cancer target, particularly in T cell acute lymphoblastic leukemia (T-ALL), with activating mutations in this gene identified in more than 50% of cases. In this study, Roti et al. describe the synthesis, characterization, and validation of JQ-FT, a first-in-class NOTCH1 inhibitor that has dual selectivity for leukemia over normal cells and NOTCH1 mutants over wild-type receptors. äLeukemia-specific delivery of mutant NOTCH1 targeted therapy (epmc).pdf DeepDyve Pubget Overpricing